Xenon Pharmaceuticals (XENE) News
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
37.04-0.52 (-1.38%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XENE news summary
We found 8 recent headlines mentioning Xenon Pharmaceuticals (XENE): 0 in the past week and 7 in the past 30 days, most often from GlobeNewswire, Nasdaq, Investing.com. For price context, XENE is down 1.38% at $37.04. The most recent story, "Xenon Reports Q3 Results; Expects X-NOVA2 Data In December And Advances Pain Programs Toward Phase 2", was published by Nasdaq on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Xenon Pharmaceuticals headlines
- Xenon Reports Q3 Results; Expects X-NOVA2 Data In December And Advances Pain Programs Toward Phase 2(RTTNews) - Xenon Pharmaceuticals Inc. (XENE), a neuroscience-focused biopharmaceutical company, on Tuesday reported third-quarter 2026 financial results and provided a business update, highlighting…NasdaqXENE, BRK.A
- Xenon Pharmaceuticals Inc. Reports Q3 2026 Financial Results and Business UpdateXenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for…NasdaqXENE, LEN.B
- Why is Xenon Pharmaceuticals stock sliding today?Investing.com
- Xenon Reports Q3 2026 Financial Results and Provides Business UpdateVANCOUVER, BC and BOSTON, MA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…GlobeNewswire
- Xenon to Present at Upcoming Investor ConferencesVANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…GlobeNewswire
- Xenon to Report Q3 2026 Financial Results on November 9, 2026VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…GlobeNewswire
- Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…GlobeNewswire
- XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.NasdaqXENE, JNJ, VNDA